HC Wainwright Reiterates “Neutral” Rating for Cytosorbents (NASDAQ:CTSO)

HC Wainwright reiterated their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Monday morning,Benzinga reports. The firm currently has a $1.00 target price on the medical research company’s stock. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

A number of other equities research analysts have also recently weighed in on the company. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th. StockNews.com started coverage on Cytosorbents in a report on Sunday, November 10th. They issued a “hold” rating for the company.

Cytosorbents Stock Up 2.6 %

Shares of NASDAQ:CTSO opened at $0.95 on Monday. The company has a market capitalization of $51.94 million, a PE ratio of -2.64 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.71 and a current ratio of 1.97. The company’s fifty day moving average is $1.13 and its 200-day moving average is $1.01. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.15.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The firm had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $9.73 million. During the same period in the prior year, the firm earned ($0.14) earnings per share. Equities research analysts predict that Cytosorbents will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Avenir Corp raised its position in shares of Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the last quarter. Sargent Investment Group LLC lifted its position in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. CM Management LLC lifted its position in Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the period. Finally, Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents during the 3rd quarter worth approximately $51,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.